Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation

被引：0
|
作者：
Kumar, Aravid S. Ravi [1 ]
Hofman, Michael S. [1 ]
机构：
[1] Univ Melbourne, Peter MacCallum Ctr Melbourne, Prostate Canc Theranost & Imaging Ctr Excellence, Mol Imaging & Therapeut Nucl Med Canc Imaging, Melbourne, Vic, Australia
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 01期
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
SAFETY;
D O I：
10.2967/jnumed.123.266638
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 22 条
  • [21] Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy
    Kamaldeep
    Wanage, Gaurav
    Sahu, Sudeep Kumar
    Maletha, Pravind
    Adnan, Aadil
    Suman, Sonam
    Basu, Sandip
    Das, Tapas
    Banerjee, Sharmila
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2021, 36 (03) : 292 - 304
  • [22] Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer
    Perrone, Elisabetta
    Giordano, Alessandro
    Calcagni, Maria Lucia
    Leccisotti, Lucia
    Moretti, Roberto
    Eismant, Aleksandr
    Ghai, Kriti
    Parkar, Tanay
    Mishra, Aditi
    Heidenreich, Axel
    Wirtz, Ralph M.
    Mueller, Joerg
    Greifenstein, Lukas
    Baum, Richard P.
    CANCERS, 2025, 17 (03)
123